Concepedia

Jaklin Gukasyan

JG

5

Publications

737

Citations

5

H-Index

2018

Active since

Affiliations

University of California, Los Angeles(Current)

Centre de Recherche en Cancérologie de Marseille

Institut Paoli-Calmettes

University of California System

Jaklin Gukasyan is an author at University of California, Los Angeles specializing in medicine, oncology, and radiation oncology.

Top concepts

MedicineOncologyImmunologyImmunotherapyRadiation OncologyPathologyLung CancerAutoimmunityPharmacologyCancer Genetics

Publications per year

2018–2022

5

Publications

5

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Aaron Lisberg, Amy L. Cummings, Jonathan W. Goldman et al. · Journal of Thoracic Oncology · 2018 · 577 citations · Full text

Advanced Nsclc, Oncology, Medicine +7

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer

Siwen Hu‐Lieskovan, Aaron Lisberg, Jesse M. Zaretsky et al. · Clinical Cancer Research · 2019 · 68 citations · Full text

Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44

Amy L. Cummings, Jaklin Gukasyan, Henry Y. Lu et al. · Nature Cancer · 2020 · 47 citations · Full text

Cancer Immunosurveillance, Non-small-cell Lung Cancer, Medicine +8

Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

Philippe Rochigneux, Aaron Lisberg, Alejandro J. Garcia et al. · Clinical Cancer Research · 2022 · 28 citations · Full text

Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

Nanruoyi Zhou, Maria A. Velez, Benjamin Bachrach et al. · Lung Cancer · 2021 · 17 citations · Full text

Autoimmune Disease, Thyroid Dysfunction, Frequent Event Post-treatment +11

Rows per page

1–5 of 5